Boston Scientific ( NYSE:BSX – Free Report ) had its price objective hoisted by Barclays from $59.00 to $60.00 in a research note published on Friday morning, Marketbeat.com reports. The brokerage currently has an overweight rating on the medical equipment provider's stock. Other analysts have also recently issued research reports about the stock. Robert W. Baird raised their target price on shares of Boston Scientific from $60.00 to $63.00 and gave the company an outperform rating in a report on Thursday.

https://www.dailypolitical.com/2023/09/23/boston-scientific-nysebsx-price-target-raised-to-60-00-at-barclays.html

#dailypolitical